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Abstract
Background: Heparan sulfate proteoglycans (HSPGs) contain glycosaminoglycan (GAG) chains
made primarily of heparan sulfate (HS). Hyperglycemia in diabetes leads to endothelial injury and
nephropathy, retinopathy and atherosclerosis. Decreased HSPG may contribute to diabetic
endothelial injury. Decreased tissue HS in diabetes has been reported, however, endothelial HS
changes are poorly studied.
Objective:  To determine total GAGs, including HS, in endothelium under hyperglycemic
conditions and the protective effect of insulin and heparin.
Methods: Confluent primary porcine aortic endothelial cells (PAECs) were divided into control,
glucose (30 mM), insulin (0.01 unit/ml) and glucose plus insulin treatment groups for 24, 48 and 72
hours. Additionally, PAECs were treated with glucose, heparin (0.5 μg/ml) and glucose plus heparin
for 72 hours. GAGs were isolated from cells and medium. GAG concentrations were determined
by the carbazole assay and agarose gel electrophoresis.
Results: GAGs were significantly increased only in control and glucose plus insulin groups at 72
versus 24 hours. Glucose decreased cell GAGs and increased medium GAGs, and insulin alone
decreased cell GAGs at all times compared to control. In the glucose plus insulin group, cell GAGs
were less than control at 24 hours, and greater than glucose or insulin alone at 48 and 72 hours
while GAGs in medium were greater than control at all times and glucose at 72 hours. Heparin
increased GAGs in glucose treated cells and medium.
Conclusion:  High glucose and insulin alone reduces endothelial GAGs. In hyperglycemic
conditions, heparin or insulin preserves GAGs which may protect cells from injury. Insulin is an
effective diabetic therapy since it not only lowers blood glucose, but also protects endothelium.
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Background
A glycosaminoglycan (GAG) is a linear, highly negatively
charged, polysaccharide macromolecule possessing a dis-
accharide repeat sequence which usually comprises an
amino sugar with D-glucosamine or galactosamine and a
uronic acid residue of either D-glucuronic acid or iduronic
acid. Based on disaccharide composition, GAG structures
are categorized into six common types including chondr-
otin sulfate (CS), dermatan sulfate (DS), heparan sulfate
(HS), keratan sulfate (KS), hyaluronic acid, and heparin.
The GAG chain is covalently attached to a core protein
through an O-link to serine or an N-link to an asparagine
residue and this structure is called a proteoglycan. Prote-
oglycans are expressed by all mammalian cells and are
found on the cell surface, in the extracellular matrix
(ECM) and intracellular granules [1].
HS is a prominent blood vessel component and the most
common GAG found on the endothelial cell (EC) surface
and in the ECM. Heparan sulfate proteoglycans (HSPGs)
are receptors for circulating growth factors and chemok-
ines that regulate cell proliferation, differentiation and
migration [2]. The interaction of HS side chains with bio-
active factors controls physiological processes of embry-
onic development, tissue repair, blood coagulation,
cartilage function and glomerular filtration [1,3,4]; and
pathological processes of wound healing, vessel forma-
tion, and tumor cell growth, adhesion, invasiveness and
metastasis [5]. HS degradation is considered a major cause
of endothelial dysfunction resulting in disturbance of vas-
cular integrity and barrier properties, due to decreased
negative charge and increased permeability, and release of
bioactive substances such as cytokines, enzymes and
growth factors bFGF and TGF-β. Changes in proteoglycan
expression, as well as structural and functional alterations
of their GAG components, are associated with cardiovas-
cular disease, cancer, inflammation, amyloidosis and dia-
betes [6-9].
Several studies suggest that HS degradation is associated
with diabetic nephropathy [10-12]. An increased glomer-
ular albumin filtration rate was observed in microalbu-
minuric patients with overt diabetes [13]. Increased
glomerular basement membrane (GBM) permeability was
associated with diminished GBM HS content [10]. Similar
changes in HS content was observed in aortic intimas of
diabetic patients [14]. HS in skin basement membrane in
patients with diabetic nephropathy was also significantly
reduced compared to those without nephropathy. Simi-
larly, reduced 35S-labeled HSPG synthesis was observed in
aorta, liver and intestinal epithelium of diabetic rats [15-
17]. This evidence suggests that changes in HS metabo-
lism occur not only in the kidney but in any tissue or
organ in the diabetic condition, indicating a link between
HS abnormalities and vascular complications both in the
micro and macro vasculature. In addition, heparanase, an
endoglucuronidase produced by ECs induced by high glu-
cose, could be responsible for the cleavage of HS chains
[18]. Heparanase activity was increased in the urine of dia-
betic patients [19] and reduction of HS moieties in the
glomeruli of patients with overt diabetic nephropathy in
type II diabetes was correlated with heparanase upregula-
tion [11]. However, specific changes in GAGs from ECs
under hyperglycemic conditions are not well studied. The
purpose of this study was to use primary porcine aortic
ECs (PAECs) under high glucose conditions as an in vitro
model to determine if changes in GAGs are seen with
hyperglycemia. Since the hormone insulin regulates glu-
cose metabolism and promotes glucose uptake and utili-
zation to reduce glucose concentration in hyperglycemia,
we also wished to determine the effect of insulin on GAG
alterations. Since our previous studies showed that
heparin also protected ECs from high glucose injury [20],
the effect of heparin was also studied.
Methods
Porcine Aortic Endothelial Cell (PAEC) Culture
Primary PAECs were cultured by the method of Gotlieb
and Spector [21]. Porcine aortic segments obtained from
local abattoirs were washed three times in Ca2+-Mg2+-free
Dulbecco's phosphate-buffered saline (CMF-DPBS) and
connective tissue was trimmed from the adventitial sur-
face. The aorta was held upright by clamping one end with
hemostats. The aortic lumen was rinsed three times with
CMF-DPBS and then filled with collagenase (Type IV,
SIGMA, St. Louis, MO, USA; 1 mg/ml in CMF-DPBS) for
six minutes. After removing the collagenase, the lumen
was gently rinsed with medium (M199 containing 5.5
mM D-glucose, without heparin or insulin, GibcoBRL,
Life Technologies, Inc., Grand Island, NY, USA) supple-
mented with 5% fetal bovine serum (FBS, GibcoBRL), 50
μg/ml penicillin (SIGMA) and 10 μg/ml streptomycin
(SIGMA). The medium with cells was plated onto 60 mm
culture dishes which were then incubated at 37°C with
5% CO2/95% air in a humidified environment. PAECs
were identified by their morphological appearance of cob-
blestone-like flattened cells, and the presence of von Wil-
lebrand factor (vWF) in initial cultures. Non-endothelial-
like cells, such as smooth muscle cells and fibroblasts
were destroyed cell by cell using a pasteur pipette and
mechanical suction before the first passage. To pass cells,
confluent cultures were washed twice with CMF-DPBS
and cells were detached by trypsin (0.025% with EDTA in
CMF-DPBS) for two or three minutes at room tempera-
ture. The cells were resuspended in medium and trans-
ferred to 60 mm dishes for further passage. For
experiments, the cells were grown in 60 or 100 mm dishes
at passage four.Cardiovascular Diabetology 2009, 8:46 http://www.cardiab.com/content/8/1/46
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Treatment of Cultures
PAECs were grown in 100 mm culture dishes (surface area
78.5 cm2/dish) with an estimated 6 million cells/dish at
confluence. Cells were incubated with four different treat-
ments (3 dishes/group) including control (serum free
medium), glucose (30 mM), insulin (0.01 unit/ml), or
glucose plus insulin in serum-free medium for 24, 48 and
72 hours. In a separate experiment ECs in 100 mm dishes
were treated with high glucose (30 mM) and/or heparin
(0.5 μg/ml), or serum free medium (control) with one
dish/group for 72 hours. Additionally, PAECs were grown
in 60 mm dishes and treated as controls or with high glu-
cose (30 mM) for 24, 48 and 72 hours with 3 dishes/
group. After the specified time interval, cell medium was
collected into 15 ml centrifuge tubes. Cells were scraped
from the dish using a cell scraper, the dish was washed
with DPBS, and cells and washings were collected into a
1.5 ml tube and centrifuged to pellet cells. The cell pellets
and medium were frozen at -80°C. Samples were freeze-
dried before they were analyzed.
Extraction of Total GAGs
Medium and cell pellets were digested by pronase (0.2
mg/ml in 0.1 M Tris buffer containing 0.1 M CaCl2, pH
8.0) for 24 hours at 37°C. Then the digested samples were
freeze-dried a second time. Total GAG extraction was per-
formed using Vivapure Ion Exchange Mini Spin Columns
(Vivascience, Germany). Urea buffer (8 M urea with 2%
w/v CHAPS (3-[(3-Cholamidopropyl) dimethylammo-
nio]-1-propanesulfonate), 500 μl, was added to the sam-
ples which were then triturated with a pipette to insure
homogenization. The samples were then centrifuged at
5000 × g for 5 minutes to remove the precipitate. The
supernatant was added into the Spin Columns which had
previously been equilibrated with 500 μl urea buffer fol-
lowed by centrifugation. The columns with supernatant
were centrifuged at 5000 × g for 10 minutes to remove the
flow-through. Columns were washed once with 500 μl of
urea buffer. Then columns were washed five times with
500 μl of 200 mM NaCl, after which total GAGs were
eluted with 3 × 100 μl of 16% NaCl. To precipitate the
total GAGs, 1.2 ml of methanol was added to the sample,
making the final methanol concentration 80% of volume,
and chilled overnight at -4°C. The total GAG fraction was
collected by centrifugation at 2500 × g for 15 min. The
resulting precipitate was dissolved in 100 μl of distilled
water.
Determination of Total GAGs by the Carbazole Assay
The carbazole assay was used to examine the total GAGs
isolated from cultured PAECs and medium in experi-
ments where cultures were treated with high glucose and/
or insulin. Briefly, 25 μl of the extracted GAG was added
to 150 μl of reagent A (25 mM Na2B4O7 in concentrated
H2SO4) which was heated at 100°C for 10 minutes. After
the reaction was cooled on ice, 5 μl of reagent B (carbazole
1.25 g in 1 L 100% ethanol) was added to the reaction
which was heated at 100°C for another 15 minutes. The
absorbance was read by spectrometry at 525 nm using a
96-well micro titer plate. The concentrations of GAGs
were calculated by comparing to a standard curve made
with heparan sulfate from porcine intestinal mucosa
(SIGMA).
Gel Electrophoresis Analysis of GAGs
Agarose gel electrophoresis described by Jaques [22] was
used to identify GAGs recovered from control ECs and
ECs treated with glucose, insulin and glucose+insulin for
72 hours, and with glucose, heparin and glucose+heparin
for 24 hours. Total GAGs were extracted from cells and
medium as describe above. Then, 3–5 μl distilled water
was added to each dried GAG sample and 2 μl of the dis-
solved GAG was added to the lanes on the agarose (1%)
gel electrophoresis slide. Slides were run in barbital buffer
(pH 8.6) for 20 minutes. Slides were then fixed in 0.01%
cetavlon for at least 2 hours. After drying, slides were
stained with 0.04% Toluidine Blue in 80% acetone and
background colour was removed with 1% acetic acid.
Heparan sulfate was identified and visualized by compar-
ing to reference heparan sulfate from porcine intestinal
mucosa (0.1 μg/μl, SIGMA).
Determination of Total HS Disaccharides in Cells and 
Medium
Additional experiments were performed for determina-
tion of HS disaccharides in cells and medium. Total GAGs
from three 60 mm dishes were combined in order to
obtain enough material for HS disaccharide analysis by
HPLC. Freeze-dried total GAG extracts were dissolved in
20 μl of 0.2 M Tris-HCl buffer (pH 8.0), then 2 μl of
Chondroitinase ACII (0.05 unit/μl) and 10 μl of Chon-
droitinase ABC (0.01 unit/μl) were added to the samples
which were incubated at 37°C overnight. Microcon YM-3,
3000 NMWL Centrifugal Filter Devices (Millipore, USA)
were used to obtain HS disaccharides. First, the device was
washed with 0.1 M NaOH once followed by washing with
50 μl H2O four to five times until the pH of the flow-
through was neutral. Second, the chondroitinase digested
samples were transferred to the devices and centrifuged at
10,000 × g for 25 minutes to remove chondroitin sulfates.
After the devices were washed with double distilled (DD)
H2O three to four times, the inserts were removed and put
into a new collecting tube. A mixture of 10 μl of hepari-
nase I (0.3 unit), heparinase II (0.1 unit) and heparinase
III (0.1 unit) in 6 mM NaCl and 3 mM Na3PO4 buffer (pH
7.1) were added to the column. After incubation at 37°C
for 24 hours to digest HS, the samples were centrifuged at
10,000 × g for 10 minutes to remove the buffer. Then HS
disaccharides were eluted by three to four additions of 50
μl DD H2O. The elution was freeze-dried and then dis-Cardiovascular Diabetology 2009, 8:46 http://www.cardiab.com/content/8/1/46
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solved in 15 μl DD H2O. Then 10 μl of the sample was
analyzed by HPLC. The analysis was performed on a post-
column fluorescence RPIP-HPLC using Shimazu LC-10Ai
system equipped with a RF535 fluorescence HPLC moni-
tor and an analytical C18 column (5 μm, 4.6 × 250 mm).
The mobile phase was A: 8% acetonitrile, 3 mM trib-
utylamine acetate, pH 5.0; B: 8% acetonitrile, 3 mM trib-
utylamine acetate, 0.2 M NaCl, pH 5.0 with a step linear
gradient 0–15 min, B 0–30%; 15–30 min, B 30–100%;
30–50 min, B 100% at a flow rate of 1.0 ml/min. Column
temperature was 55°C. Post-column reaction reagents
were C: 1% 2-cyanoacetamite and D: 0.75 M NaOH with
a flow rate at 0.2 ml/min. The reaction temperature was
120°C and detected with Ex 346 nm, Em 410 nm.
Statistical Analysis
Data for total GAGs analysed by the carbazole assay are
expressed as mean +/- standard error (SE) from three
dishes per group. A one-way ANOVA was used to deter-
mine significant differences between groups. Values of P <
0.05 were considered to be statistically significant. A one-
tailed t-test was used to determine significant differences
between total GAGs at 24 and 72 hour.
Results
Total GAGs in Cultures
Total GAGs were extracted from cells and medium grown
in 100 mm dishes after 24, 48 and 72-hour treatment with
glucose (30 mM) and/or insulin (0.01 unit/ml).
24 hours
The GAG concentration was significantly decreased in
high glucose or insulin treated cells compared to control
(Figure 1A). When high glucose was present, insulin sig-
nificantly increased GAG concentrations in cells com-
pared to insulin alone, although concentrations were still
significantly less than control cells. In medium from the
same cultures, GAG concentrations were significantly
increased in high glucose and decreased with insulin treat-
ment compared to control. GAG concentrations in
medium were significantly increased by glucose+insulin
compared to control and insulin alone treated cultures.
When the ratio of GAGs in cells and medium was
expressed as a percentage, there were more GAGs in cells
than medium in control and insulin alone treated cul-
tures, while in high glucose treated cultures with and with-
out insulin the ratio was reversed (Figure 1B). The
percentage of total GAGs in glucose treated cells was sig-
nificantly lower than control and with insulin alone. The
percentage of total GAGs in high glucose treated medium
with and without insulin was significantly increased com-
pared to control and insulin alone.
48 hours
GAG concentrations in cells were significantly decreased
in high glucose or insulin treated compared to control cul-
tures. Total GAGs in insulin treated cells when high glu-
cose was present was significantly greater than high
glucose or insulin alone and similar to control cells (Fig-
ure 2A). In the same cultures GAG concentration in
medium was significantly increased in high glucose and
high glucose plus insulin treated compared to control cul-
tures. When GAG percentages were calculated more GAGs
were found in medium than cells for all groups. The per-
centage of total GAGs in cells was decreased in all treat-
ments compared to controls and increased in insulin plus
high glucose compared to high glucose or insulin alone
(Figure 2B). The percentages of total GAGs in medium
were increased in all treatment groups compared to con-
trol and decreased in high glucose plus insulin treated cul-
tures compared to high glucose and insulin alone.
72 hours
Relative GAG concentrations in cells were similar to those
seen at 24 hours and significantly less than control for all
treatment groups. High glucose+insulin significantly
increased GAG concentrations compared to high glucose
or insulin alone (Figure 3A). The GAG concentrations in
medium were increased in glucose+insulin treated cul-
tures compared to the other three groups. When GAG per-
centages in cells and medium were calculated more GAGs
were found in medium than cells for all experimental
groups while in controls the cells contained most of the
GAGs. The percentage of total GAGs significantly
decreased in cells and increased in medium for all treat-
ments compared to control (Figure 3B).
Comparison of Total GAGs in Cultures at Different Times
GAG concentrations were significantly increased in con-
trol cells and in control and glucose+insulin treated
medium at 72 compared to 24 hours. GAG concentrations
in control cells at 72 hours were greater than high glucose
and insulin alone treated cells at 72 hours. GAG concen-
trations in glucose plus insulin treated medium were
greater than all other treatment groups at 72 hours (Figure
4A and 4B). Significantly more GAGs were found in cells
plus medium in control and high glucose plus insulin
treated cultures at 72 compared to 24 hours and to other
groups at 72 hours (Figure 4C).
GAG Analysis by Gel Electrophoresis
In order to better define GAGs extracted from cells treated
with high glucose and/or insulin for 72 hours, GAGs were
exposed to agarose gel electrophoresis, as shown in Figure
5. In agreement with the carbazole assay at 72 hours, con-
trol cells showed a higher GAG content than medium,
while with glucose treatment there were less GAGs in cells
than medium. Glucose plus insulin treatment showed aCardiovascular Diabetology 2009, 8:46 http://www.cardiab.com/content/8/1/46
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GAGs from Cultured Endothelial Cells and Medium at 24 Hours Figure 1
GAGs from Cultured Endothelial Cells and Medium at 24 Hours. Cells were treated with high glucose (30 mM) and/
or insulin (0.01 unit/ml) for 24 hours. Total GAGs were isolated from cells (white bar) and medium (grey bar) and determined 
by the carbazole assay. Three dishes/group. Data were analyzed by a one-way ANOVA. Significantly different than: a, Control; 
b, Glucose; c, Insulin. p < 0.05.
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GAGs from Cultured Endothelial Cells and Medium at 48 Hours Figure 2
GAGs from Cultured Endothelial Cells and Medium at 48 Hours. Cells were treated with high glucose (30 mM) and/
or insulin (0.01 unit/ml) for 48 hours. Total GAGs were isolated from cells (white bar) and medium (grey bar) and determined 
by the carbazole assay. Three dishes/group. Data were analyzed by a one-way ANOVA. Significantly different than: a, Control; 
b, Glucose; c, Insulin. p < 0.05.
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GAGs from Cultured Endothelial Cells and Medium at 72 Hours Figure 3
GAGs from Cultured Endothelial Cells and Medium at 72 Hours. Cells were treated with high glucose (30 mM) and/
or insulin (0.01 unit/ml) for 72 hours. Total GAGs were isolated from cells (white bar) and medium (grey bar) and determined 
by the carbazole assay. Three dishes/group. Data were analyzed by a one-way ANOVA. Significantly different than: a, Control; 
b, Glucose; c, Insulin. p < 0.05.
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Total GAGs Increased with Culture Time in Both Cells and Medium Figure 4
Total GAGs Increased with Culture Time in Both Cells and Medium. Cells were treated with high glucose (empty 
dot, 30 mM), insulin (solid triangle, 0.01 unit/ml), glucose+insulin (empty triangle) and control (solid dot) for 24, 48, and 72 
hours (3 dishes/group). Total GAGs isolated from cells (A), medium (B) and cells +medium (C) and determined by the carba-
zole assay are shown. A one-tailed t-test was used to determine significant differences between treatment at 24 and 72 hour. 
Significantly greater than: a, same group at 24 hours; b, glucose at 72 hours; c, insulin at 72 hours; d, glucose+insulin at 72 
hours; e, control at 72 hours. p < 0.05.Cardiovascular Diabetology 2009, 8:46 http://www.cardiab.com/content/8/1/46
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greater GAG content than insulin treatment alone both in
cells and medium. In insulin alone treated cultures, the
faster migrating component was reduced in cells com-
pared to control and high glucose treated cells. Since
heparin interferes with HS determination in HPLC and
the carbazole assay, GAGs extracted from cells treated
with high glucose and/or heparin for 72 hours were only
determined and distinguished on gel electrophoresis, as
shown in Figure 6. Control and glucose treated cells
showed results similar to those mentioned above for glu-
cose and/or insulin treatment. Glucose plus heparin had
more GAG content in cells compared to glucose or
heparin alone and in medium compared to heparin
alone. In medium the fast migrating band was greatest for
heparin plus glucose treatment while the slower migrating
bands were greater for the treated group than control.
Correlation of Total HS Disaccharides and Total GAGs
Control cells and cells treated with high glucose (30 mM)
(three 60 mm dishes/group) were cultured for 24, 48 and
72 hours. Total GAGs and HS disaccharides were obtained
from the same samples. There was a good correlation
between total HS disaccharides and total GAGs obtained
(Figure 7). The type of HS disaccharides recovered did not
differ between high glucose and control samples (data not
shown).
Discussion
Syndecans and perlecan are major HSPGs synthesized and
secreted by ECs. Syndecans are mainly expressed on the
cell surface and perlecan is presented in the ECM [23].
Heparan sulfate chains derived from HSPG are the main
GAGs found in ECs [24]. In the present study, we found
that total HS determined by HPLC correlated well with
total GAGs determined by the carbazole assay (Figure 7).
Therefore, total GAGs likely reflect total HS present within
endothelium. The GAGs were extracted from the entire
cultured endothelial monolayer including mainly synde-
cans and perlecan.
Total GAGs from the cells and medium were determined
when cultured ECs were exposed to high glucose and/or
insulin. At the earliest observed time (24 hours), cells
treated with high glucose showed a reduction in total
GAGs (Figure 1). The observation that cell total GAGs
decreased and medium GAGs increased up to 72 hours
with high glucose treatment (Figure 3, 4, and 5) are con-
sistent with the finding that GAG contents from syndecan-
1 and perlecan were decreased in cultured primary ECs
treated with high glucose for two and five days [25,26].
Decreased cell GAGs suggest hyperglycemia could induce
HSPG degradation or inhibit HSPG synthesis in ECs. The
possible consequences of decreased GAGs are reduced
Gel Electrophoresis Showing GAGs in Cells and Medium in Cultures Treated with Glucose and/or Insulin for 72 Hours Figure 5
Gel Electrophoresis Showing GAGs in Cells and Medium in Cultures Treated with Glucose and/or Insulin for 
72 Hours. Lanes: S, standard, heparan sulfate from porcine intestinal mucosa; C, control; G, glucose; I, insulin; G+I, glu-
cose+insulin (3 dishes combined/group)
Cells
Medium
S                   C                  G                        I                     G+I   
S                        C                  G             I                  G+I   
-
+
-
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interaction of several biofactors such as growth factors,
coagulation factors, chemokines, adhesion molecules,
and lipoprotein lipase with HSPG in the vasculature [27].
Loss of these biofactors is likely to induce endothelial
injury. We previously observed endothelial injury follow-
ing addition of high glucose in the same culture model
[20]. Although our culture model uses aortic ECs, and ECs
in macro- and micro-vessels have different properties,
both are characterized by the same pathological features
in diabetes mellitus. Endothelial injury likely contributes
to diabetic cardiovascular complications both in micro-
and macro-vessels such as nephropathy, retinopathy and
atherosclerosis [28,29].
Increased total GAGs in medium with high glucose treat-
ment suggest that GAGs are released from cell proteogly-
can core proteins. The core protein may remain on the cell
surface. This was indirectly confirmed by immunoprecip-
itation assays where the core protein of syndecan-1
remained on ECs and was expressed at lower intensity in
medium from high glucose treated ECs [24]. Similarly,
immunostaining studies showed that reduction in HS
GAGs in the GBM under diabetic conditions was not
accompanied by a reduction in the HSPG core protein
[30]. As well, decreased HSPG synthesis by human aortic
ECs in high glucose conditions was not the result of a
decrease in GAG size, further suggesting that entire GAG
chains were released into culture medium [25]. It is
unlikely that GAGs are further degraded in medium.
Insulin controls blood glucose utilization and influences
the metabolism of fat and protein. Insulin also has effects
on the expression of numerous genes. Insulin alone
decreased GAG concentration in cells at all time points in
our study. In a study of regulation of HSPG metabolism
and hepatocyte growth by insulin and phosphatidylinosi-
tol, insulin markedly stimulated the rate of internaliza-
tion of matrix HSPG and phospholipase C and therefore
may control cell surface HSPG turnover [31]. Thus insulin
may regulate enzymes involved in metabolism of prote-
oglycans. Insulin promoted shedding of syndecan ectodo-
mains, from 3T3-L1 adipocytes, by an unknown
mechanism [32]. However, it is unknown whether these
changes are coordinated by phosphatidylinositol, the sec-
ond messenger in the action of binding insulin to its
receptor, and whether shedding of syndecans are seen in
ECs in response to insulin. In our studies there was a trend
that insulin alone increased GAGs in culture medium as
culturing time increased (Figure 4) which may indicate
HSPG turnover or shedding of syndecan into medium,
however, GAGs were significantly reduced in 72 hour cul-
tures compared to control suggesting that GAG synthesis
Gel Electrophoresis Showing GAGs in Cells and Medium Treated with Glucose and/or Heparin for 72 Hours Figure 6
Gel Electrophoresis Showing GAGs in Cells and Medium Treated with Glucose and/or Heparin for 72 Hours. 
Lanes: S, standard, heparan sulfate from porcine intestinal mucosa; C, control; G, glucose; H, heparin; G+H, glucose+heparin (1 
dish/group).Cardiovascular Diabetology 2009, 8:46 http://www.cardiab.com/content/8/1/46
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may also be inhibited. These limited observations cannot
define the precise mechanisms involved in insulin reduc-
tion of GAGs in cultured ECs, and further investigation is
required. Considerable evidence indicates that vascular
endothelium is a physiological target of insulin and a
potential link between insulin resistance and atheroscle-
rosis [33,34]. Endothelial dysfunction is one of the earli-
est detectable signs in insulin resistance [35]. Our present
study shows that decreased GAG content in insulin alone
treated cells may lead to endothelial dysfunction caused
by GAG degradation and/or inhibition of GAG synthesis.
The evidence for insulin influencing different cultured
cells under high glucose conditions is varied and contro-
versial. Studies on cultured mesangial cells treated with
glucose and insulin showed insulin did not influence
HSPG content independent of the ambient glucose levels
[36]. Insulin was unable to correct the 30 mM glucose
induced reduction in HSPG synthesis of rat glomerular
epithelial cell layers that resemble the GBM [37]. How-
ever, reduction in chondroitin sulfate proteoglycan syn-
thesis found in articular cartilage in diabetic rats could be
completely restored by administration of insulin [38].
Administration of large doses of insulin restored HSPG
synthesis in basement membrane following reduction of
HSPG by implantation of Engelbreth-Holm-Swarm (EHS)
tumor cells in diabetic mice [39]. Our current studies
showed that: insulin increased GAGs in high glucose
treated cells compared to insulin alone at all times and to
high glucose alone at 48 and 72 hours; insulin increased
medium GAGs at all times compared to control, at 24 and
72 hours compared to insulin alone; insulin was able to
maintain high glucose treated cell+medium GAGs at con-
trol levels at 72 hours (Figure 4C). Previous studies noted
that insulin alone increased endothelin-1 (ET-1) levels
[40]. Perhaps insulin maintains HSPGs under hyperglyc-
emic conditions through its effects on ET-1. Although
these studies indicate that insulin has the potential to
improve hyperglycemia induced alteration of HSPG in
ECs, the effect is time dependent. It is possible that insulin
Correlation of Total HS Disaccharides and Total GAGs in Cultured Endothelial Cells Figure 7
Correlation of Total HS Disaccharides and Total GAGs in Cultured Endothelial Cells. Control cells and cells 
treated with high glucose (30 mM) were cultured for 24, 48 and 72 hours (3 dishes/group). Total GAGs were isolated, after 
cells and medium separately from the three dishes were determined by the carbazole assay. HS disaccharides were obtained by 
heparinase digestion and determined by RPIP-HPLC systems.
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modulation of proteoglycan metabolism under hypergly-
cemic conditions is cell or tissue specific and specific for
individual species of proteoglycans.
Heparin used as an antithrombotic drug, is also consid-
ered a potent vasodilator [41], and lowers blood pressure
[42]. Heparin has the ability to inhibit heparanase upreg-
ulation induced by high glucose in cultured ECs [18]. Our
results suggest that heparin increases GAG content in cells
treated with high glucose suggesting the protective effect
of heparin on ECs. Taken together with evidence that
heparin stimulates HS synthesis and modification of HS
in ECs [43,44], further suggests that heparin's protective
action may be due to an increase in GAG synthesis or inhi-
bition of heparanase production.
Conclusion
ECs are targets for hyperglycemia in diabetes mellitus
resulting in cardiovascular complications. Alteration of
GAGs synthesized by cells is an important pathological
mechanism, which can be correlated with cell injury by
hyperglycemia. Insulin or heparin undoubtedly protects
cell GAGs from degradation and/or increases GAG synthe-
sis which may protect cells from high glucose injury.
These results confirm the efficacy of insulin as a therapeu-
tic drug for the diabetic patient since it not only lowers
blood glucose levels, but also protects the vasculature. The
effectiveness of heparin on the protection of ECs through
maintaining GAG content was also confirmed. Elevated
insulin alone without hyperglycemia may have a damag-
ing effect. The exact mechanism of insulin influence on
EC HSPG metabolism needs to be further elucidated at
the levels of gene expression and cell signaling pathways.
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